Posts Archive

Multiple Myeloma Research Consortium MMRC-089: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3...

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)...

CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...

NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM Belantamab mafodotin (GSK2857916) is a...

A.R.R.O.W.2 NCT03859427: Phase 3: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and...

DREAMM 3 Relapsed & Refractory Myeloma v NCT04162210: Phase 3 - Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone...

Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...

IFM2017_03 NCT03993912: Phase 3 - Lenalidomide and SC Daratumumab vs Lenalidomide and Dexamethasone in NDMM(IFM2017_03) This is a Phase...

NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed...

NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM Ixazomib + Pomalidomide + Dexamethasone In MM This is a Phase I/II...

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma Kd This...

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab,...

CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...

NCT03562169: Phase 3: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) NCT03562169:...

KarMMa-3 bb2121 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma...

Perseus Study NDMM Newly Diagnosed Multiple Myeloma EMN 17 Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to...

PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...

NCT03729804: Phase 3: Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in...

IFM 2018-04 NCT03606577: Phase 2: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell...